Primmune Therapeutics Presents Data Evaluating PRTX007 as an Antiviral at the 35th International Conference on Antiviral Research (ICAR)

Mar 21, 2022 | Press Releases

— PRTX007 exhibits activation of the innate immune system in both cellular and murine animal models against respiratory syncytial virus (RSV) — — Findings demonstrate broad-spectrum antiviral activity and suitability of PRTX007 as a clinical candidate to support...

Primmune Therapeutics to Participate in the 32nd Annual Oppenheimer Healthcare Conference

Mar 10, 2022 | Press Releases

SAN DIEGO, March 10, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...

Primmune Therapeutics to Participate in the 12th Annual Biocom Global Life Science Partnering Conference

Feb 24, 2022 | Press Releases

SAN DIEGO, February 24, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...

Primmune Therapeutics Presents Interim Analysis of Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)

Feb 14, 2022 | Press Releases

— Oral administration of PRTX007 exhibits favorable safety profile, rapid conversion to TLR7 agonist PRX034, and activation of the innate immune system, without an increase in proinflammatory factors — SAN DIEGO, February 14, 2022 – Primmune Therapeutics, a biotech...

Primmune Therapeutics to Present Clinical Data from Phase 1 Study Evaluating PRTX007 at the Conference on Retroviruses and Opportunistic Infections (CROI 2022)

Feb 7, 2022 | Press Releases

SAN DIEGO, February 7, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat viral diseases and cancers, today announced that they will present data related to PRTX007, a novel, orally administered, small molecule...

Primmune Therapeutics Receives $8.4 Million in Second Tranche of Series A Financing

Nov 4, 2021 | Press Releases

SAN DIEGO, November 4, 2021 – Primmune Therapeutics today announced that it has received $8.4 million in a second tranche of the Company’s Series A financing. The total proceeds for the equity raised in the Series A was $31.4 million. These funds will be used to...